Phase II Study of Pembrolizumab and Itacitinib for First Line Treatment of Metastatic NSCLC Expressing PD-L1 M. E. Marmarelis,D. Mathew,J. M. Bauml, W. -T. Hwang, J. Zhang,A. Singh,C. D'Avella,C. Davis, D. Ye,L. Sun, C. Ciunci, N. Zhang,C. Aggarwal, R. B. Cohen,A. J. Minn, E. J. Wherry, C. J. LangerJOURNAL OF THORACIC ONCOLOGY（2022）引用 0|浏览3暂无评分关键词Immunotherapy, JAK, pembrolizumabAI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
